Target Name: PARP8
NCBI ID: G79668
Other Name(s): ARTD16 | FLJ21308 | ADP-ribosyltransferase diphtheria toxin-like 16 | PARP8 variant 2 | pART16 | MGC42864 | PARP8_HUMAN | Poly (ADP-ribose) polymerase-8 (PARP-8) | PARP-8 | Protein mono-ADP-ribosyltransferase PARP8 (isoform 1) | Poly(ADP-ribose) polymerase family member 8, transcript variant 2 | Protein mono-ADP-ribosyltransferase PARP8 | Poly [ADP-ribose] polymerase 8 | poly(ADP-ribose) polymerase family member 8

Inhibiting PARP8: A Potential Drug Target for Various Diseases

PARP8 (Artd16) is a protein that is expressed in various tissues throughout the body. It is a key player in the DNA damage response pathway, which is a critical process that helps the body repair damage to its DNA. PARP8 has also been shown to play a role in the regulation of cell growth, apoptosis, and inflammation.

Due to its involvement in these processes, PARP8 has been identified as a potential drug target or biomarker. Researchers are interested in developing drugs that can inhibit the activity of PARP8 and treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One approach to inhibiting the activity of PARP8 is to target its activity with small molecules, such as drugs that can bind to specific PARP8 proteins. These drugs can be developed by a variety of methods, including virtual screening, high-throughput screening, and structural bioinformatics. Once a potential drug is identified, it can be tested for its effectiveness in preclinical models of the disease.

Another approach to inhibiting the activity of PARP8 is to target its activity with antibodies. These antibodies can be designed to recognize specific PARP8 proteins and can be used to treat the disease by blocking the activity of the protein. Antibody-based therapies have the advantage of being highly specific and can be administered in a safe and effective manner.

In addition to its potential as a drug target or biomarker, PARP8 is also of interest as a potential therapeutic target for certain diseases. For example, PARP8 has been shown to be involved in the regulation of cancer cell survival and has been associated with the development of certain types of cancer. Therefore, inhibiting the activity of PARP8 may be a promising approach to treating cancer.

Overall, the potential of PARP8 as a drug target or biomarker is significant and holds promise for the treatment of a variety of diseases. Further research is needed to fully understand the activity of PARP8 and to develop safe and effective drugs that can inhibit its activity.

Protein Name: Poly(ADP-ribose) Polymerase Family Member 8

Functions: Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins

More Common Targets

PARP9 | PARPBP | PARS2 | PART1 | PARTICL | PARVA | PARVB | PARVG | Parvovirus initiator complex | PASD1 | PASK | Patatin-like phospholipase domain-containing protein | PATE1 | PATE2 | PATE3 | PATE4 | PATJ | PATL1 | PATL2 | PATZ1 | PAUPAR | PAWR | PAX1 | PAX2 | PAX3 | PAX4 | PAX5 | PAX6 | PAX6-AS1 | PAX7 | PAX8 | PAX8-AS1 | PAX9 | PAXBP1 | PAXBP1-AS1 | PAXIP1 | PAXIP1-AS2 | PAXIP1-DT | PAXX | PBDC1 | PBK | PBLD | PBOV1 | PBRM1 | PBX1 | PBX2 | PBX3 | PBX3-DT | PBX4 | PBXIP1 | PC | PCA3 | PCAF complex | PCARE | PCAT1 | PCAT14 | PCAT18 | PCAT19 | PCAT2 | PCAT29 | PCAT4 | PCAT5 | PCAT6 | PCAT7 | PCBD1 | PCBD2 | PCBP1 | PCBP1-AS1 | PCBP2 | PCBP2-OT1 | PCBP2P2 | PCBP3 | PCBP3-AS1 | PCBP4 | PCCA | PCCA-DT | PCCB | PCDH1 | PCDH10 | PCDH11X | PCDH11Y | PCDH12 | PCDH15 | PCDH17 | PCDH18 | PCDH19 | PCDH20 | PCDH7 | PCDH8 | PCDH9 | PCDH9-AS3 | PCDH9-AS4 | PCDHA1 | PCDHA10 | PCDHA11 | PCDHA12 | PCDHA13 | PCDHA14 | PCDHA2 | PCDHA3